IL-2/IL-2R研究简史及药物开发
IL-2/IL-2R受体里程碑研究
IL-2/IL-2R药物开发
向上滑动阅览
1. Morgan DA, Ruscetti FW, GalloRC: Selective in vitro growth of T lymphocytes from normal human bone marrows.Science 1976, 193: 1007e1008
2. J.W. Mier, R.C. Gallo,Purification and some characteristics of human T-cell growth factor fromphytohemagglutinin-stimulated lymphocyte-conditioned media, Proc.Natl. Acad.Sci. USA (1980)
3. aniguchi T,et al: Structure andexpression of a cloned cDNA for human interleukin-2. Nature 1983, 302:305e310
4. Cosman, D.et al, (1984).Cloning, sequence and expression of human interleukin-2 receptor. Nature 312,768–771.
5. Leonard, W.J.,etal.(1984).Molecular cloning and expression of cDNAs for the human interleukin-2 receptor.Nature 311, 626–631.
6. Nikaido, T., et al (1984).Molecular cloning of cDNA encoding human interleukin-2 receptor. Nature 311,631–635.
7. Sharon, M., et al. (1986).Novel interleukin-2 receptor subunit detected by cross-linking underhigh-affinity conditions. Science 234, 859–863.
8. Takeshita, T., et al. (1990).An associated molecule, p64, with high-affinity interleukin 2 receptor. Int.Immunol. 2, 477–480.
9. Saito, Y.,et al. (1991).Biochemical evidence for a third chain of the interleukin-2 receptor. J. Biol.Chem. 266, 22186–22191.
10. X. Wang, M. Rickert, K.C.Garcia, Structure of the quaternary complex of interleukin-2 with Its α, ß, andγc Receptors. Science (80-) 310 (2005) 1159 LP–1163
11. Lafreniere R, Rosenberg SA.1985. Successful immunotherapy of murine experimental hepatic metastases withlymphokine activated killer cells and recombinant interleukin 2. Cancer Res45(8):3735–3741.
12. Rosenberg SA, et al. 1985.Observations on the systemic administration of autologous lymphokine-activatedkiller cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med 313(23):1485–1492.
13. Rosenberg SA. 2014. IL-2: thefirst effective immunotherapy for human cancer. J Immunol 192(12):5451–5458.
14. Shanafelt AB, et al. 2000. AT-cell-selective interleukin 2 mutein exhibits potent antitumor activity and iswell tolerated in vivo. Nat Biotechnol 18(11):1197–1202.
15. Carnemolla B, Borsi L, Balza Eet al (2002) Enhancement of the antitumor properties of interleukin-2 byits targeted delivery to the tumor blood vessel extracellular matrix. Blood99(5):1659– 1665
16. Alexy Orozco Valencia，et al，Interleukin-2 as immunotherapeutic in the autoimmune diseases，International Immunopharmacology 81 (2020) 1062962
17. Rosanne Spolski，et al，Biology and regulation of IL-2: from molecular mechanisms to human therapy，Nat Rev Immunol . 2018 Oct;18(10):648-659.
Webinar
第47期
Jake Yang,PhD.
苏州大学药学院 特聘教授
哈尔滨工业大学化学系，后分别在上海交通大学和新加坡国立大学取得材料科学硕士学位，2008年获得美国马里兰大学机械工程博士学位。先后在马里兰大学和约翰霍普金斯医学院从事博士后研究工作，2013年起任职约翰霍普金斯病理系青年教师，2016加入美国食品药品管理局，2019年任职美国卫生院研究员。
在约翰.霍普金斯获得2012年度青年科学奖、2017年度获北美华人色谱青年科学家等奖励，2018年获得美国食品药品管理局科学成就奖。
Webinar
参与方式